ENTPD1 and neoplasm: Experimental studies, both in vitro and in vivo with knockout mouse models, have demonstrated that inhibiting CD39 effectively reactivates T-cell and NK-cell anti-tumor responses, facilitating the suppression of hepatic growth of metastatic melanoma tumors [40].